NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference

NewAmsterdam Pharma Company announced that Michael Davidson, M.D., CEO, will present at the SVB Securities Global Biopharma Conference on February 16, 2023, at 1:00 p.m. ET.

Rhea-AI Summary

NewAmsterdam Pharma Company announced that Michael Davidson, M.D., CEO, will present at the SVB Securities Global Biopharma Conference on February 16, 2023, at 1:00 p.m. ET. The presentation can be accessed live via the investor relations section of their website with an archived replay available later.

The company focuses on developing oral therapies for cardiometabolic diseases. Its lead candidate, obicetrapib, has shown promising Phase 2b trial results, achieving a median 51% reduction in LDL-C levels in high-risk cardiovascular patients. Recently, NewAmsterdam completed a business combination with Frazier Lifesciences, securing around $328 million in proceeds to further its development efforts.

Argus Session date unavailable

+0.24% session move Open Argus

Details

News Market Reaction – NAMS

The recorded move for NAMS in the trading session of this news was +0.24%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NAARDEN, the Netherlands and MIAMI, Feb. 09, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will present at SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 at 1:00 p.m. ET.

A live webcast of the presentation will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam (Nasdaq: NAMS) is a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease (“CVD”) patients. Results from NewAmsterdam’s ROSE Phase 2b trial (presented at AHA Scientific Sessions in 2021) included observations that patients receiving obicetrapib 10 mg experienced a median reduction in LDL-C of 51% versus baseline in patients on high-intensity statin therapy (vs. a 7% reduction in the placebo arm). Based in the Netherlands, NewAmsterdam recently completed a business combination with Frazier Lifesciences Acquisition Corporation (“FLAC”), a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners. Proceeds from this transaction were approximately $328 million, prior to deducting transaction expenses, comprising approximately $93 million in funds from the former FLAC trust account and approximately $235 million from the concurrent, oversubscribed PIPE financing, which was co-led by Frazier Healthcare Partners and Bain Capital Life Sciences and included leading institutional investors. In June 2022, NewAmsterdam entered into an exclusive licensing agreement with the Menarini Group for the commercialization of obicetrapib in Europe, while retaining all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer’s disease. For more information, please visit: www.newamsterdampharma.com.

Media Contact 
Spectrum Science on behalf of NewAmsterdam
Carmen Lopez
P: 1 773-306-6285
clopez@spectrumscience.com 

Investor Contact 
Stern Investor Relations on behalf of NewAmsterdam
Hannah Deresiewicz
P: 1 212-362-1200
hannah.deresiewicz@sternir.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Michael Davidson presenting at the SVB Securities Global Biopharma Conference?

Michael Davidson will present on February 16, 2023, at 1:00 p.m. ET.

Where can I watch the NewAmsterdam Pharma presentation live?

The presentation will be available via webcast on NewAmsterdam Pharma's investor relations website.

What are the key results from NewAmsterdam's ROSE Phase 2b trial?

The trial reported a median LDL-C reduction of 51% with obicetrapib 10 mg versus baseline in patients on high-intensity statin therapy.

How much funding did NewAmsterdam acquire from their business combination?

NewAmsterdam secured approximately $328 million in proceeds from its business combination with Frazier Lifesciences.

What is the purpose of obicetrapib in NewAmsterdam's research?

Obicetrapib is being investigated as an LDL-C lowering therapy for patients with high-risk cardiovascular disease.